Minimal change disease is defined by an abrupt onset of heavy proteinuria, low blood albumin, and elevated blood lipids. Under the electron microscope, the hallmark is the diffuse effacement of podocyte foot processes, the interdigitating projections that anchor these cells to the glomerular basement membrane and dynamically regulate filtration permeability. Yet light microscopy typically reveals an unremarkable glomerular architecture, and renal biopsies from many patients show no significant infiltration of T cells. This paradox has haunted nephrologists for decades: aberrant T cell activation is clearly implicated in driving podocyte injury, but the mechanism by which T cells are mobilized without ever visibly entering the kidney has remained elusive. Compounding the clinical problem, roughly twenty to thirty percent of adult patients develop steroid dependence or resistance, and some progress to end-stage renal disease.

The research team, led by investigators at Nanjing University Medical School and collaborating institutions, approached the problem by integrating clinical analysis with in vitro and in vivo experimental models. Their central hypothesis centered on extracellular vesicles—lipid bilayer-enclosed nanoscale particles that shuttle proteins, lipids, nucleic acids, and metabolites between cells. Exosomes, the smallest of these vesicles at thirty to one hundred fifty nanometers, have previously been found at elevated levels in the urine of patients with metabolic syndrome-associated kidney disease, renovascular hypertension, and preeclampsia, with their abundance correlating with proteinuria severity. What remained undefined was whether podocyte-derived exosomes could actually mediate communication between podocytes and T cells through antigen presentation.

In laboratory experiments, the researchers cultured mouse podocytes with a model antigen and interferon-gamma, an inflammatory cytokine. When naive T cells from OT-I transgenic mice—whose receptors specifically recognize the model antigen—were co-cultured with these activated podocytes, flow cytometry revealed a striking upregulation of the activation markers CD69 and CD25. Critically, adding GW4869, an inhibitor of exosome secretion, abolished this activation, indicating that the podocytes were stimulating T cells through released exosomes rather than direct contact. Characterization of the isolated vesicles confirmed their exosomal identity: they carried the canonical markers TSG101, ALIX, and CD63 but lacked the negative control protein calnexin, displayed a characteristic cup-shaped morphology under transmission electron microscopy, and measured fifty to one hundred fifty nanometers in diameter.

The mechanistic crux of the study lies in major histocompatibility complex class I molecules. Interferon-gamma stimulation significantly increased the expression of MHC-I, MHC-II, and the costimulatory molecules CD80 and CD86 on podocyte-derived exosomes. When the researchers generated podocytes deficient in MHC-I through lentiviral knockdown, exosomes from these cells completely failed to activate T cells. In vivo, the team depleted professional antigen-presenting cells by whole-body irradiation and then injected MHC-I-deficient exosomes alongside OT-I CD8-positive T cells into mice with puromycin aminonucleoside-induced minimal change disease. These mice exhibited significantly lower urinary protein-to-creatinine ratios and markedly fewer activated interferon-gamma-positive T cells in renal lymph nodes and spleen compared with controls receiving intact exosomes. The conclusion was unambiguous: CD8-positive T cell activation by podocyte exosomes is strictly dependent on MHC-I-mediated antigen presentation.

Perhaps the most elegant finding concerns the division of labor between podocyte exosomes and dendritic cells. While exosomes alone could trigger T cell activation, they could not drive T cell proliferation without dendritic cells present. In irradiated mice lacking dendritic cells, podocyte exosomes still activated kidney-resident memory T cells and worsened proteinuria, but systemic T cell expansion was blunted. When the researchers reconstituted dendritic cells by bone marrow-derived cell transfer, the full pathological cascade returned. This suggests a biphasic mechanism the authors describe as local activation followed by systemic amplification: exosomes mediate antigen presentation to tissue-resident memory T cells within the kidney to ignite early inflammation, while dendritic cells relay antigenic signals to secondary lymphoid organs, where they recruit and expand effector T cell populations. The data favor a reprocessing model in which dendritic cells internalize exosomes, degrade their cargo, and load peptides onto their own MHC-I molecules, rather than simply acquiring pre-formed complexes on their surface.

To establish clinical relevance, the team developed an autologous pairing system using samples from twenty patients with biopsy-confirmed minimal change disease and twenty with lupus nephritis. Plasma from each patient was split so that podocyte-derived exosomes, identified by the podocyte marker podocalyxin, could be isolated and paired with naive CD8-positive T cells from the same individual’s blood. Exosomes from both patient groups carried high levels of MHC-I, MHC-II, CD80, and CD86. Exposure to these autologous exosomes triggered robust T cell receptor signaling, evidenced by increased phosphorylation of ZAP-70 and Lck, followed by CD69 and CD25 upregulation, substantial proliferation by seventy-two hours, and elevated interferon-gamma secretion. Mass spectrometry of patient-derived exosomes identified 108 proteins unique to minimal change disease samples, including immunoglobulin variable region components and complement proteins, and bioinformatic screening against the Immune Epitope Database flagged twelve candidate autoantigens, with dermcidin prioritized on the basis of an HSP70-binding domain and an embedded HLA-A*03 epitope. Levels of exosomal MHC-I and CD80 correlated strongly with disease severity measures.

The therapeutic implications were tested through two complementary strategies. Pharmacological inhibition with GW4869 reduced renal exosome burden, lowered the urinary albumin-to-creatinine ratio, and decreased effector CD8-positive interferon-gamma-positive T cells in renal lymph nodes and spleen. More precisely, the team engineered podocyte-specific manipulation of Rab27a, a membrane-binding GTPase that governs the docking of multivesicular endosomes with the plasma membrane and thereby controls exosome release. Genetic overexpression of Rab27a in podocytes accelerated disease, while podocyte-specific knockout suppressed exosome secretion even more effectively than GW4869 and attenuated disease progression. Because GW4869 lacks tissue specificity and could disrupt beneficial exosome secretion in immune and endothelial cells, the podocyte-restricted genetic approach provides a cleaner proof of principle, pointing toward kidney-targeted nanocarrier delivery systems or CRISPR-based spatiotemporal control of Rab27a as future therapeutic avenues.

The study’s authors acknowledge that the candidate autoantigens remain at the level of computational prediction and will require direct validation through MHC-I immunopeptidomics and autologous T cell priming assays. Mouse models also cannot fully recapitulate human disease, and questions remain about whether exosomes influence B cells and macrophages as well. Nevertheless, the work fundamentally redefines podocytes as non-classical antigen-presenting cells and identifies a concrete, targetable pathway—Rab27a-dependent exosome release—linking podocyte injury to systemic T cell immunity. For a disease in which twenty to thirty percent of adult patients fail first-line steroid therapy, the prospect of intercepting these molecular messengers before they mobilize the immune system represents a compelling new frontier in precision nephrology.

Subject of Research: Podocyte-derived exosome-mediated antigen presentation and CD8-positive T cell activation in minimal change disease

Article Title: Podocyte-derived exosomes instruct dendritic cell-dependent CD8 + T cell activation and proliferation in renal inflammation

Article References: Qian, B., Mao, S., Chen, Y., Liu, Y., Zhang, M., Zhu, D., Zen, K., Wang, Y., Liu, Z., & Li, L. (2026). Podocyte-derived exosomes instruct dendritic cell-dependent CD8+ T cell activation and proliferation in renal inflammation. Journal of Advanced Research, 88, 885-898. https://doi.org/10.1016/j.jare.2026.01.032

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.032

Keywords: podocytes, exosomes, minimal change disease, CD8 T cells, MHC-I, dendritic cells, Rab27a, nephrotic syndrome, antigen presentation, renal inflammation, extracellular vesicles, proteinuria

Rare inherited renal disorders, or RIRD, are a genetically diverse group of conditions that include Alport syndrome, nephrotic syndrome, Dent disease, Lowe syndrome, nephrogenic diabetes insipidus and congenital anomalies of the kidney and urinary tract. Individually each is uncommon, but together they contribute substantially to illness and death, particularly among children and young adults. Many patients progress to end-stage renal disease, requiring dialysis or transplantation. Because these diseases are hereditary, a precise molecular diagnosis matters enormously: it can guide treatment, inform family planning, and identify relatives who may carry the same risk.

Next-generation sequencing has transformed the diagnostic landscape for such conditions. Whole-exome sequencing, which reads the protein-coding portions of the genome, can reveal the causative mutation in a substantial fraction of cases. Yet the technology has also created a new bottleneck. Sequencing routinely flags variants of uncertain significance, DNA changes whose effect on protein function is unknown. Under current classification frameworks such as those of the American College of Medical Genetics and Genomics, these variants cannot be used alone to make a diagnosis. Functional evidence, showing that a variant actually disrupts a gene or protein, is often the decisive factor in reclassifying them as pathogenic or benign.

That evidence is scarce for populations that are underrepresented in global genetic databases, and Sri Lankans are a prime example. Variants that are rare or absent in European and East Asian reference cohorts are frequently classified as uncertain simply because nobody has studied them. The Sri Lankan population, with its complex history and distinct genetic architecture, carries variants that may be unique to the island or shared with South Asian neighbors but poorly documented elsewhere. Building population-specific functional data is therefore not an academic luxury; it directly determines whether a family in Colombo receives a definitive diagnosis or an ambiguous report.

The research team, led by K. M. Fathima Rizna and corresponding author Dineshani Hettiarachchi under the senior authorship of Vajira H. W. Dissanayake, set out to functionally characterize variants previously identified through whole-exome sequencing in Sri Lankan patients with clinically diagnosed rare inherited renal disorders. Their strategy had two complementary arms. The first was real-time quantitative polymerase chain reaction, or RT-qPCR, a laboratory technique that measures how actively a gene is transcribed into messenger RNA in patient samples compared with controls. The second was in silico protein modeling, computational methods that predict the three-dimensional structure of a protein and estimate how a specific amino acid change or truncation might destabilize it.

The gene expression results were striking. Several genes showed reduced expression in patient samples: AVPR2, which carries a missense change and encodes the arginine vasopressin receptor 2 central to water balance in the kidney; DAAM2, a gene involved in actin regulation within kidney filter cells; OCRL, mutated in Lowe syndrome and Dent disease; and CLCN5, a chloride channel gene also implicated in Dent disease. In contrast, NPHS2, which encodes the podocin protein essential for the glomerular filtration barrier, and COL4A5, the collagen gene behind X-linked Alport syndrome, showed increased expression. Most notably, DAAM2 expression was strongly downregulated, pointing to a potential functional relevance for the variant of uncertain significance associated with it. DAAM2 variants have previously been shown to cause nephrotic syndrome through disruption of the actin cytoskeleton, making this finding particularly compelling.

The computational modeling told a consistent story. Truncating variants in COL4A5, OCRL and AVPR2 were predicted to cause significant structural disruption, either by removing essential functional domains or by introducing premature stop signals that terminate protein synthesis early. A missense variant in AVPR2 was predicted to affect a transmembrane region of the receptor, the segment that spans the cell membrane and is critical for the receptor to sit correctly in its cellular location and transmit the vasopressin signal. When the team compared these predictions with their laboratory measurements, the two lines of evidence converged: genes whose proteins were predicted to be severely damaged showed absent or reduced expression in patient samples, a pattern consistent with the modeling results.

This convergence is the methodological heart of the study. Neither approach alone is conclusive. Gene expression changes can be secondary consequences of disease rather than causes, and structural predictions depend on the quality of available templates and the assumptions built into tools such as homology modeling and AlphaFold-based structure prediction. But when a predicted structural catastrophe in a protein aligns with measurably reduced transcription of its gene in the tissue of an affected patient, the case for pathogenicity becomes far stronger. Integrating protein modeling with gene expression analysis, the authors argue, provides functional insights that neither method delivers on its own, and supports the potential reclassification of selected variants of uncertain significance.

The clinical implications reach beyond Sri Lanka. For the families enrolled in the study, functional evidence may convert an uncertain result into an actionable diagnosis, enabling cascade testing of relatives, more accurate recurrence risk counseling, and in some cases access to targeted management. For the wider field, the study demonstrates a practical, relatively low-cost workflow, RT-qPCR plus computational modeling, that laboratories in resource-limited settings can deploy to add functional evidence where expensive experimental systems are unavailable. It also adds Sri Lankan variant data to the global pool, gradually correcting the Eurocentric bias that still distorts variant interpretation worldwide.

Limitations remain, and the authors are careful about what their data can and cannot show. Expression measurements were performed on available patient samples rather than in purpose-built disease models, and computational predictions, however sophisticated, ultimately require experimental validation through approaches such as model organism studies or cellular assays before variants can be definitively reclassified. Patient data could not be deposited in public repositories for ethical and privacy reasons, though it is available from the corresponding author on reasonable request. Nevertheless, the study marks a meaningful step toward diagnostic precision for rare inherited kidney disease in a population that has long waited for its genomes to be read on their own terms, and it offers a template other underrepresented populations can follow.

Subject of Research: Functional characterization of genetic variants associated with rare inherited renal disorders in the Sri Lankan population

Article Title: Functional characterization of genetic variants associated with rare inherited renal disorders in the Sri Lankan population

Article References: Rizna, K. M. F., Noordeen, N., Bandara, W. M. M. S., Hewavitharana, H., Hendalage, B., Neththikumara, N., Hettiarachchi, D., & Dissanayake, V. H. W. (2026). Functional characterization of genetic variants associated with rare inherited renal disorders in the Sri Lankan population. Molecular Genetics and Genomics, 301(1), Article 201. https://doi.org/10.1007/s00438-026-02524-x

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02524-x

Keywords: rare inherited renal disorders, whole-exome sequencing, variants of uncertain significance, RT-qPCR, in silico protein modeling, Sri Lanka, kidney genetics, Alport syndrome, nephrotic syndrome, DAAM2, AVPR2, COL4A5

Writing in Biomedical Microdevices, a team of researchers from Anhui University of Chinese Medicine, the University of Science and Technology of China, and collaborating institutions in Hefei, China, reports that hemodynamic disruption, the weakening of the mechanical forces normally exerted by flowing blood, is associated with degradation of the endothelial glycocalyx, a hairlike carbohydrate coating on the surface of glomerular blood vessels. This gel-like layer, composed of membrane-bound proteoglycans studded with glycosaminoglycans such as heparan sulfate, serves two roles simultaneously: it acts as a selective permeability barrier that repels negatively charged plasma proteins, and it functions as a mechanosensor that translates fluid shear stress into biochemical signals that keep endothelial cells healthy. The team’s central finding, supported by both an animal model and two microfluidic organ-on-a-chip platforms, is that when the mechanical stimulation of flow diminishes, the glycocalyx erodes, the endothelial cytoskeleton falls into disarray, inflammatory adhesion molecules rise to the cell surface, and the glomerular barrier becomes progressively leakier.

The clinical backdrop makes this line of inquiry compelling. Nephrotic syndrome is not simply a disease of leaky filters. It is characterized by heavy proteinuria alongside a hypercoagulable state and abnormal blood rheology, meaning the blood itself behaves differently, with increased viscosity and heightened clotting tendency. That combination creates a potential vicious cycle: if sluggish, abnormally viscous flow means less shear stress delivered to the vessel wall, and if reduced shear stress degrades the glycocalyx that keeps the barrier intact, then the rheological consequences of nephrotic syndrome could actively feed the barrier injury that defines it. Prior clinical work, including a 2025 multicenter cross-sectional analysis in Kidney360, has documented alterations in coagulation and endothelial function in nephrotic patients, but the mechanobiological chain connecting altered microhemodynamics to glycocalyx breakdown had remained largely speculative.

To test the idea, the researchers first turned to a well-established animal model: rats in which nephrotic syndrome is induced by adriamycin, a chemotherapeutic agent also known as doxorubicin whose cardiotoxic and nephrotoxic side effects have long been exploited by researchers to create reproducible proteinuric kidney disease. The treated animals developed the expected signature of the syndrome, with hypercoagulability and increased blood viscosity measurable alongside heavy urinary protein excretion. Critically, high-resolution imaging of the glomerular microvasculature, aided by lanthanum tracer transmission electron microscopy techniques that make the glycocalyx layer visible, revealed marked loss of the endothelial glycocalyx structure and its key components in the adriamycin-treated animals. The scaffolding of the vessel lining, in other words, had crumbled along with the barrier function of the kidney.

The most revealing part of the in vivo work came from a deliberate pharmacological comparison. The team treated separate groups of nephrotic rats with two mechanistically distinct drugs. Sulodexide, a glycosaminoglycan compound that has been used clinically to address microalbuminuria and that prior studies have shown to remodel and restore the glycocalyx in sepsis models, acted on the structural side of the problem. Prednisone acetate, the classic glucocorticoid of nephrology practice, works mainly through immunosuppression and has been shown to act directly on podocytes, stabilizing their cytoskeleton through glucocorticoid receptor signaling. The results split cleanly. Sulodexide ameliorated the hemorheological abnormalities and restored glycocalyx integrity, while prednisone predominantly reduced proteinuria and inflammatory adhesion molecule expression. The dissociation suggests that glycocalyx loss and inflammatory activation are partially separable axes of the disease, and that repairing the endothelial sugar coat is a distinct therapeutic target from calming inflammation.

Animal models, however, cannot cleanly separate cause from effect. Adriamycin is a direct toxin, and the glycocalyx damage it causes might simply reflect poisoning of endothelial cells rather than altered blood flow. To isolate the mechanical variable, the team built two microfluidic devices: a vascular-on-a-chip and a glomerulus-on-a-chip. These platforms, which culture living endothelial cells within engineered microchannels perfused by programmable pumps, allow researchers to dictate exactly what shear stress the cells experience. The team exposed endothelial cells to a series of stepwise reductions in perfusion flow rate, systematically stripping away the mechanical stimulation that vessels normally deliver, while keeping the chemical environment constant. What they observed was a progressive and dose-like response. As flow diminished, the glycocalyx thinned and degraded, the actin cytoskeleton lost its organized architecture, endothelial cells flipped into an activated, pro-inflammatory state marked by adhesion molecules, and in the glomerulus-on-a-chip, the permeability of the reconstructed filtration barrier measurably increased.

This chip-based evidence elevates the study from correlation toward mechanism. The finding dovetails with a growing body of mechanobiology showing that the endothelial glycocalyx is not a passive scaffold but a dynamic antenna, protruding into the flow stream and deforming under shear stress. Reviews of the field, including work on basal glycocalyx responses to shear stress published in Frontiers in Cell and Developmental Biology, describe how the layer participates in flow sensing through the glypican and syndecan proteoglycan families, transmitting mechanical information to the cytoskeleton and to junctional complexes. Earlier microfluidic work has shown that reducing shear stress disorganizes the actin cytoskeleton, and that laminar flow shapes the morphology and functional phenotype of glomerular endothelial cells in particular. The new study stitches these threads together in a disease context, proposing an endothelial-glycocalyx-centered mechanobiological pathway through which the hypercoagulable, viscous blood of nephrotic syndrome could erode the very barrier whose failure defines the disease.

The authors are careful, and appropriately so, about the limits of the claim. Their own data did not confirm that adriamycin-induced injury was entirely mediated by hemodynamic alterations. Direct toxic effects on podocytes and tubules, along with inflammatory cascades, clearly operate in parallel, and the study positions reduced flow-associated mechanical stimulation as a plausible contributor rather than the sole cause. That framing is scientifically honest and, arguably, more useful clinically, because it reframes nephrotic syndrome as a disease of converging insults, a direct chemical injury layered with an inflammatory assault and compounded by the biomechanical consequences of altered blood rheology. Any one of those axes might be attacked therapeutically, and the study’s drug comparison hints at how: glucocorticoids address inflammation and podocyte stabilization, while glycosaminoglycan-based agents such as sulodexide address the structural and rheological dimension.

The broader significance lies in what organ-on-a-chip technology makes possible. By decoupling flow from chemistry, toxicity, and systemic factors, the vascular-on-a-chip and glomerulus-on-a-chip platforms used in this work offer a template for interrogating hemodynamic contributions to other barrier diseases, from sepsis-related vascular leak to diabetic nephropathy, where glycocalyx degradation is also implicated. The authors have placed all raw data, protocols, and analytical procedures in a public repository to support reproducibility. For patients with nephrotic syndrome, many of whom face relapsing disease and the side effects of long-term steroids, the study opens a tantalizing prospect: that protecting or rebuilding a microscopic sugar coating, and in doing so restoring the mechanical conversation between blood and vessel wall, could one day help seal the kidney’s failing filter from the blood side.

Subject of Research: Mechanobiological degradation of the endothelial glycocalyx driving glomerular filtration barrier injury in nephrotic syndrome

Article Title: Hemodynamic disruption triggers glomerular barrier injury via endothelial glycocalyx degradation in nephrotic syndrome

Article References: Feng, Y., Wang, S., Wang, Y., Yang, M., Miao, C., Wang, Q., Ding, W., Tan, H., Luo, T., & Xu, F. (2026). Hemodynamic disruption triggers glomerular barrier injury via endothelial glycocalyx degradation in nephrotic syndrome. Biomedical Microdevices, 28(4), Article 67. https://doi.org/10.1007/s10544-026-00850-w

Image Credits: AI Generated

DOI: 10.1007/s10544-026-00850-w

Keywords: nephrotic syndrome, endothelial glycocalyx, glomerular filtration barrier, fluid shear stress, organ-on-a-chip, glomerulus-on-a-chip, hemodynamics, proteinuria, sulodexide, adriamycin nephropathy, mechanobiology, microfluidics